Cargando…
NI-07 VALIDATION OF MACHINE LEARNING BASED HIGH GRADE GLIOMA MR SEGMENTATION VIA METHIONINE PET
Treatment planning and lesion-follow up are generally conducted by contrast-enhanced MRI in glioma patient care. On the other hand, there are, however, substantial concerns whether MRI actually reflects the extension or activity of this neoplasm, which information should be fundamentally important a...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213347/ http://dx.doi.org/10.1093/noajnl/vdz039.120 |
_version_ | 1783531785651486720 |
---|---|
author | Kinoshita, Manabu Ozaki, Tomohiko Arita, Hideyuki Kagawa, Naoki Kanemura, Yonehiro Fujimoto, Yasunori Sakai, Mio Watanabe, Yoshiyuki Nakanishi, Katsuyuki Shimosegawa, Eku Hatazawa, Jun Kishima, Haruhiko |
author_facet | Kinoshita, Manabu Ozaki, Tomohiko Arita, Hideyuki Kagawa, Naoki Kanemura, Yonehiro Fujimoto, Yasunori Sakai, Mio Watanabe, Yoshiyuki Nakanishi, Katsuyuki Shimosegawa, Eku Hatazawa, Jun Kishima, Haruhiko |
author_sort | Kinoshita, Manabu |
collection | PubMed |
description | Treatment planning and lesion-follow up are generally conducted by contrast-enhanced MRI in glioma patient care. On the other hand, there are, however, substantial concerns whether MRI actually reflects the extension or activity of this neoplasm, which information should be fundamentally important at every step when treating this disease. As a matter of fact, the authors of this investigation have already shown that there is no difference in tumor cell density within areas with and without contrast enhancement (J Neurosurg. 2016,125(5):1136–1142.) and furthermore that the geometry of MRI based-radiation treatment planning is significantly altered when methionine PET is integrated for this purpose (J Neurosurg. 2018 published on-line). Regardless of these concerns, there is great interest in the research community to construct a machine learning based fully automated brain tumor segmentation tool specific for gliomas using MRI. The authors attempted to validate this method by comparing MRI-based automated brain tumor segmentation and methionine PET. Consecutively collected 45 high-grade gliomas (GBM-26, grade3-19) were analyzed. BraTumIA, an automated brain tumor segmentation tool, was used for machine learning based lesion segmentation. At the same time, lesions were segmented using various thresholds on methionine PET. The authors observed 40% of pseudo-positive and 90% of pseudo-negative error on BraTumIA based lesion segmentation when methionine PET was considered as ground truth with a cut-off of 1.3 in T/N ratio. Pseudo-negative error was as high as 60% even if the threshold was elevated to 2.0. Although machine learning based glioma segmentation is expected to expand in both research and clinical use, the observed results caution the use of MRI as ground truth of spatial extension of glioma and researchers should be reminded that this imaging modality may obscure the true behavior of the disease within the patient in some cases. |
format | Online Article Text |
id | pubmed-7213347 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-72133472020-07-07 NI-07 VALIDATION OF MACHINE LEARNING BASED HIGH GRADE GLIOMA MR SEGMENTATION VIA METHIONINE PET Kinoshita, Manabu Ozaki, Tomohiko Arita, Hideyuki Kagawa, Naoki Kanemura, Yonehiro Fujimoto, Yasunori Sakai, Mio Watanabe, Yoshiyuki Nakanishi, Katsuyuki Shimosegawa, Eku Hatazawa, Jun Kishima, Haruhiko Neurooncol Adv Abstracts Treatment planning and lesion-follow up are generally conducted by contrast-enhanced MRI in glioma patient care. On the other hand, there are, however, substantial concerns whether MRI actually reflects the extension or activity of this neoplasm, which information should be fundamentally important at every step when treating this disease. As a matter of fact, the authors of this investigation have already shown that there is no difference in tumor cell density within areas with and without contrast enhancement (J Neurosurg. 2016,125(5):1136–1142.) and furthermore that the geometry of MRI based-radiation treatment planning is significantly altered when methionine PET is integrated for this purpose (J Neurosurg. 2018 published on-line). Regardless of these concerns, there is great interest in the research community to construct a machine learning based fully automated brain tumor segmentation tool specific for gliomas using MRI. The authors attempted to validate this method by comparing MRI-based automated brain tumor segmentation and methionine PET. Consecutively collected 45 high-grade gliomas (GBM-26, grade3-19) were analyzed. BraTumIA, an automated brain tumor segmentation tool, was used for machine learning based lesion segmentation. At the same time, lesions were segmented using various thresholds on methionine PET. The authors observed 40% of pseudo-positive and 90% of pseudo-negative error on BraTumIA based lesion segmentation when methionine PET was considered as ground truth with a cut-off of 1.3 in T/N ratio. Pseudo-negative error was as high as 60% even if the threshold was elevated to 2.0. Although machine learning based glioma segmentation is expected to expand in both research and clinical use, the observed results caution the use of MRI as ground truth of spatial extension of glioma and researchers should be reminded that this imaging modality may obscure the true behavior of the disease within the patient in some cases. Oxford University Press 2019-12-16 /pmc/articles/PMC7213347/ http://dx.doi.org/10.1093/noajnl/vdz039.120 Text en © The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Kinoshita, Manabu Ozaki, Tomohiko Arita, Hideyuki Kagawa, Naoki Kanemura, Yonehiro Fujimoto, Yasunori Sakai, Mio Watanabe, Yoshiyuki Nakanishi, Katsuyuki Shimosegawa, Eku Hatazawa, Jun Kishima, Haruhiko NI-07 VALIDATION OF MACHINE LEARNING BASED HIGH GRADE GLIOMA MR SEGMENTATION VIA METHIONINE PET |
title | NI-07 VALIDATION OF MACHINE LEARNING BASED HIGH GRADE GLIOMA MR SEGMENTATION VIA METHIONINE PET |
title_full | NI-07 VALIDATION OF MACHINE LEARNING BASED HIGH GRADE GLIOMA MR SEGMENTATION VIA METHIONINE PET |
title_fullStr | NI-07 VALIDATION OF MACHINE LEARNING BASED HIGH GRADE GLIOMA MR SEGMENTATION VIA METHIONINE PET |
title_full_unstemmed | NI-07 VALIDATION OF MACHINE LEARNING BASED HIGH GRADE GLIOMA MR SEGMENTATION VIA METHIONINE PET |
title_short | NI-07 VALIDATION OF MACHINE LEARNING BASED HIGH GRADE GLIOMA MR SEGMENTATION VIA METHIONINE PET |
title_sort | ni-07 validation of machine learning based high grade glioma mr segmentation via methionine pet |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213347/ http://dx.doi.org/10.1093/noajnl/vdz039.120 |
work_keys_str_mv | AT kinoshitamanabu ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet AT ozakitomohiko ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet AT aritahideyuki ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet AT kagawanaoki ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet AT kanemurayonehiro ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet AT fujimotoyasunori ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet AT sakaimio ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet AT watanabeyoshiyuki ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet AT nakanishikatsuyuki ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet AT shimosegawaeku ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet AT hatazawajun ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet AT kishimaharuhiko ni07validationofmachinelearningbasedhighgradegliomamrsegmentationviamethioninepet |